Literature DB >> 7880450

The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine.

S L Cappendijk1, D Fekkes, M R Dzoljic.   

Abstract

Norharman (20 mg/kg, i.p.) and ibogaine (40 mg/kg, i.p.) significantly attenuated naloxone (4 mg/kg, i.p.)-precipitated withdrawal syndrome in morphine-dependent rats. Several withdrawal signs, such as teeth-chattering, chewing, penile licking and diarrhoea, were decreased by both norharman and ibogaine. In addition, norharman reduced also the withdrawal grooming and rearing. It is concluded that both norharman and ibogaine are inhibitors of withdrawal syndrome in morphine-dependent rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7880450     DOI: 10.1016/0166-4328(94)90080-9

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  6 in total

1.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

Review 2.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

3.  In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism.

Authors:  Suzan Owaisat; Robert B Raffa; Scott M Rawls
Journal:  Neurosci Lett       Date:  2012-08-03       Impact factor: 3.046

Review 4.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

5.  Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine.

Authors:  Nicholas MacInnes; Sheila L Handley
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

6.  Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation.

Authors:  Tamara Antonio; Steven R Childers; Richard B Rothman; Christina M Dersch; Christine King; Martin Kuehne; William G Bornmann; Amy J Eshleman; Aaron Janowsky; Eric R Simon; Maarten E A Reith; Kenneth Alper
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.